Caricamento...
Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
BACKGROUND: In Phase 3 studies of ustekinumab, a fully human monoclonal IL‐12/23p40 antibody approved for moderate‐to‐severe Crohn's disease, patients entered a long‐term extension after completing 8 weeks of induction and 44 weeks of maintenance treatment. Efficacy through 92 weeks and safety...
Salvato in:
| Pubblicato in: | Aliment Pharmacol Ther |
|---|---|
| Autori principali: | , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6032827/ https://ncbi.nlm.nih.gov/pubmed/29797519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14794 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|